Microsoft: Earnings Estimates For Q1 2022

Microsoft (NASDAQ: MSFT) will be reporting its first quarter financial results on the 26th after the markets close. Analysts have a consensus $339.26 12-month price target on the company, via a total of 41 analysts, with 17 analysts having strong buy ratings. 22 analysts meanwhile have buy ratings, and 2 analysts have hold ratings on the company. The street high sits at a $384 price target, and the lowest target sits at $281.78.

25 analysts have revenue estimates for the first quarter. The mean revenue estimate between all 25 analysts is $44.97 billion; this number has been revised upwards from $41.90 billion at the start of April. The highest revenue estimate is $44.77 billion, while the lowest is $43.66 billion.

Onto EBITDA estimates, there are currently 4 analysts who have first-quarter EBITDA estimates. The mean is currently $22.28 billion, with this number having been revised upwards from $20.35 billion at the start of April. The street high estimate currently sits at $22.76 billion in EBITDA and the lowest is $21.56 billion.

Analysts estimate that quarterly earnings per share will come in at $2.07, with this number being revised upwards from $1.90 at the start of April. Street high is $2.17 and the lowest estimate is $2.03 per share for the quarter.


Information for this briefing was found via Edgar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

When 4% of Global Copper Disappears Overnight | David Gower – Emerita Resources

Mining M&A: Gold X2 Acquires Kesselrun Resources

They Said Oil Was Dead. They Were Wrong. | Michael Judson – Record Resources

Recommended

Military Seizes Power in Madagascar After President Flees

Altamira Gold Hits 395.5 Metres Of 0.4 g/t Gold At Maria Bonita

Related News

Canaccord Reiterates $1.75 Price Target For Mind Medicine Following Roadshow Event

This morning, Canaccord released a flash update for Mind Medicine (NEO: MMED) with highlights from...

Monday, September 28, 2020, 11:02:24 AM

GFL Environmental: BMO Lifts Target To US$42 After Asset Divesture

At the start of the month, GFL Environmental Inc. (TSX: GFL) announced that they completed...

Friday, October 15, 2021, 11:34:00 AM

Paypal: Consensus Price Target Jumps To $314 Following Q1 Results

Paypal Holdings (NASDAQ: PYPL) ended last week down almost 5% following the release of its...

Tuesday, May 11, 2021, 10:48:00 AM

Fortuna Silver: Q2 Production Gold Production Comes Up Short On BMO Estimates

Fortuna Silver Mines Inc. (TSX: FVI) yesterday reported its second-quarter production results. The company announced...

Tuesday, July 12, 2022, 12:36:00 PM

Antibe Therapeutics: Canaccord Upgrades Price Target To $16.50

Earlier this week, Antibe Therapeutics (TSXV: ATE) announced a strategic licensing deal with Nuance Pharm...

Thursday, February 11, 2021, 04:07:00 PM